Ładuje się......
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin...
Zapisane w:
| Główni autorzy: | , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Dove Medical Press
2012
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3363148/ https://ncbi.nlm.nih.gov/pubmed/22661900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S31758 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|